Chronic Kidney Disease Epidemiology and Market Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chronic Kidney Disease – Market Insight, Epidemiology and Market Forecast -2032” report has been added to ResearchAndMarkets.com’s offering. This “Chronic Kidney Disease- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the … [Read more…]

Cansativa Group and Akanda Corp. to Bring New Medical Cannabis Flowers to Germany

FRANKFURT AM MAIN & LONDON–(BUSINESS WIRE)–Akanda Corp. (“Akanda”) (NASDAQ: AKAN) and Cansativa GmbH (“Cansativa Group”) today jointly announced a new cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars. This collaboration allows the Cansativa platform to supply the German market with dried flowers from Akanda’s EU-GMP certified indoor grow … [Read more…]

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration

BSI certification agency has granted Abionic’s abioSCOPE® device and PSP test the IVDR certification for in-vitro diagnostics. This certification complies with Europe’s new In-vitro Diagnostic Regulation (IVDR), and will be required for products sold within the EU from May 2022 onward. A transitional regulation allows established, non-IVDR-certified products to be sold and used if they … [Read more…]

CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program

TORONTO–(BUSINESS WIRE)–First paragraph, first sentence of release should read: Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, announced today that it has established an at-the-market equity program (the “ATM Program”) that allows Cybin to issue and sell up to USD$35,000,000 of common shares … [Read more…]

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (“the Company”) announced today that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the Company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is … [Read more…]

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Approximately 6,000 participants 5 years of age and older will be enrolled in Lyme disease-endemic regions in Europe and the U.S.  NEW YORK & SAINT-HERBLAIN, France–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) … [Read more…]

HCA Healthcare to Donate up to $400,000 to Kentucky Flood Relief Efforts

NASHVILLE, Tenn.–(BUSINESS WIRE)–HCA Healthcare, Inc. (NYSE: HCA), one of the nation’s leading healthcare providers, today announced that it will contribute up to $400,000 in funding, colleague matching and in-kind donations to support organizations providing relief services to eastern Kentucky communities struck by historic flooding. HCA Healthcare will contribute to the following organizations: $100,000 to the … [Read more…]

iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for 510K Clearance

Prospective Study Earlier Presented at the Annual Meeting of the American Academy of Ophthalmology (AAO) and Selected for Panel Discussion as an Outstanding work. First prospective clinical study on AI and color retinal image-based early diagnosis of AMD in outpatient settings and first such submission to FDA. Study design reviewed with FDA at a pre-submission … [Read more…]

Invacare Reports Results for Second Quarter 2022

Achieved sequential improvement in profitability and free cash flow ELYRIA, Ohio–(BUSINESS WIRE)–Invacare Corporation (NYSE: IVC) (“Invacare” or the “company”) today reported results for the quarter ended June 30, 2022. Executive Summary Reflecting on the quarter, Matt Monaghan, chairman, president, and chief executive officer, said “In 2Q22, we achieved sequential revenue growth of 4.7% in mobility … [Read more…]